Safety and Efficacy of Tenalisib Given in Combination with Romidepsin in Patients with Relapsed/Refractory T-Cell Lymphoma: Final Results from a Phase I/II Open Label Multi-Center Study
Swaminathan P. Iyer(The University of Texas MD Anderson Cancer Center), Brad M. Haverkos(University of Colorado Cancer Center), Deepa Jagadeesh(University of Massachusetts Chan Medical School), Tatyana Feldman(Hackensack University Medical Center), Suchitra Sundaram(Roswell Park Comprehensive Cancer Center), Auris Huen(University of Pennsylvania), Don A. Stevens(Norton Healthcare), Timothy M. Kuzel(Rush University), Weiyun Z. Ai(City College of San Francisco), Juan Pablo Alderuccio(Sylvester Comprehensive Cancer Center), Mary Jo Lechowicz(Emory University), Nishitha Reddy(Vanderbilt University), Craig Okada(Oregon Health & Science University), Ajit Nair(Rhizen Pharmaceuticals (Switzerland)), Ann Mohrbacher(University of Southern California), Prajak J. Barde(Rhizen Pharmaceuticals (Switzerland)), Kasi V. Routhu(Rhizen Pharmaceuticals (Switzerland))
Cited by 15
Related Papers
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
|The Lancet|2018|733
Pivotal Phase III Trial of Two Dose Levels of Denileukin Diftitox for the Treatment of Cutaneous T-Cell Lymphoma
|Journal of Clinical Oncology|2001|610